Clinical trial
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Serotonin Reuptake Inhibitor
NCT01275248 is registered in ClinicalTrials.gov with Transcept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Serotonin Reuptake Inhibitor
- Lead sponsor
- Transcept Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2011
- Completion date
- September 30, 2015
- Enrollment
- 130 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.